Earnings summaries and quarterly performance for Rezolute.
Executive leadership at Rezolute.
Board of directors at Rezolute.
Research analysts covering Rezolute.
Recent press releases and 8-K filings for RZLT.
Rezolute Faces Legal Investigation Following Clinical Trial Failure
RZLT
Legal Proceedings
- Faruqi & Faruqi, LLP is investigating potential claims against Rezolute, Inc. (NASDAQ: RZLT) on behalf of investors who suffered significant losses.
- This investigation follows a sharp decline in Rezolute's shares on December 11, 2025, after disappointing topline results from its Phase 3 sunRIZE clinical trial for ersodetug.
- The clinical trial failed to meet both its primary and key secondary endpoints, as the highest dose of ersodetug did not show statistically significant reductions in hypoglycemia events compared to placebo.
- During intraday trading, RZLT stock collapsed from approximately $10.94 to an intraday low near $0.90, representing an approximate 85–90% drop.
4 days ago
Rezolute Shares Plummet After Drug Trial Failure
RZLT
Legal Proceedings
New Projects/Investments
- On December 11, 2025, Rezolute, Inc. (RZLT) shares crashed as much as 90% during intraday trading following the announcement of the failure of its Phase 3 sunRIZE trial for ersodetug.
- The drug, ersodetug, intended to treat hypoglycemia caused by hyperinsulinism, did not meet its primary or secondary endpoints in the trial.
- The news prompted national shareholders rights firm Hagens Berman to open an investigation into whether Rezolute misled investors about erso's efficacy and commercial prospects.
- Analysts reacted swiftly, with one reportedly slashing Rezolute's rating from outperform to neutral and the price target from $12 to $1.
7 days ago
Rezolute Faces Investigation Following Failed Clinical Trial Results
RZLT
Legal Proceedings
Demand Weakening
Product Launch
- Faruqi & Faruqi, LLP is investigating potential claims against Rezolute, Inc. (NASDAQ: RZLT).
- This investigation follows a sharp decline in Rezolute shares on December 11, 2025, due to disappointing topline results from its Phase 3 sunRIZE clinical trial for ersodetug.
- The clinical trial for ersodetug, Rezolute's lead drug candidate for treating congenital hyperinsulinism, failed to meet both its primary and key secondary endpoints.
- The highest dose of ersodetug did not show statistically significant reductions in hypoglycemia events compared to placebo.
Jan 8, 2026, 6:12 PM
Rezolute provides updates on sunRIZE and Expanded Access Program for hyperinsulinism
RZLT
New Projects/Investments
- Rezolute's Phase 3 sunRIZE study for congenital hyperinsulinism did not meet its primary or key secondary endpoints, though the company believes ersodetug shows pharmacologic activity. Rezolute plans to meet with the FDA in Q1 2026 to discuss the path forward for this indication.
- In the Expanded Access Program (EAP) for tumor hyperinsulinism, 75% of patients receiving IV dextrose/TPN achieved complete discontinuation. This data supports the ongoing upLIFT study, which anticipates topline results in the second half of 2026.
Jan 7, 2026, 12:00 PM
Rezolute, Inc. Provides sunRIZE Study Insights and Updates on Tumor Hyperinsulinism Program
RZLT
New Projects/Investments
Guidance Update
- Rezolute, Inc. announced that its Phase 3 sunRIZE study for congenital hyperinsulinism did not meet its primary or key secondary endpoints, though the company believes the data supports ersodetug's activity against hypoglycemia.
- The company plans to engage with the FDA in Q1 2026 to discuss the path forward for congenital hyperinsulinism.
- In its Expanded Access Program for tumor hyperinsulinism, 75% of patients achieved complete discontinuation of IV dextrose/TPN with ersodetug, and topline results for the Phase 3 upLIFT study are anticipated in the second half of 2026.
- Rezolute is well-capitalized with $152 million in cash, providing a runway to mid-2027, and estimates a total global market opportunity of over $1 billion for ersodetug.
Jan 7, 2026, 11:10 AM
Rezolute Investigated by Faruqi & Faruqi Following Clinical Trial Failure
RZLT
Legal Proceedings
Profit Warning
- Faruqi & Faruqi, LLP is investigating potential claims against Rezolute, Inc. (RZLT).
- The investigation stems from a sharp decline in Rezolute's share price on December 11, 2025, following disappointing topline results from its Phase 3 sunRIZE clinical trial for ersodetug.
- The clinical trial failed to meet both its primary and key secondary endpoints, as the highest dose of ersodetug did not show statistically significant reductions in hypoglycemia events compared to placebo.
- On December 11, 2025, RZLT's stock price tumbled from approximately $10.94 to an intraday low near $0.90, representing an 85–90% drop.
Jan 6, 2026, 3:41 PM
Rezolute Faces Legal Investigation Following Clinical Trial Failure
RZLT
Legal Proceedings
Profit Warning
- Faruqi & Faruqi, LLP is investigating potential claims against Rezolute, Inc. (RZLT) on behalf of investors who suffered significant losses.
- The investigation follows the disappointing topline results from Rezolute's Phase 3 sunRIZE clinical trial for ersodetug, announced on December 11, 2025.
- The trial, which aimed to treat congenital hyperinsulinism, failed to meet both its primary and key secondary endpoints, with the highest dose not showing statistically significant reductions in hypoglycemia events versus placebo.
- On December 11, 2025, RZLT shares collapsed approximately 85–90%, falling from around $10.94 to an intraday low near $0.90.
Jan 3, 2026, 12:41 PM
Rezolute Shares Decline 90% Following Lead Drug Trial Failure
RZLT
Legal Proceedings
Profit Warning
- Rezolute, Inc. (RZLT) shares cratered as much as 90% on December 11, 2025, after the company announced the failure of its Phase 3 sunRIZE trial for ersodetug ("erso").
- The Phase 3 study for erso, a potential treatment for hypoglycemia caused by hyperinsulinism, did not meet its primary or secondary endpoints.
- Following the trial failure, Hagens Berman opened an investigation into whether Rezolute may have misled investors about erso's efficacy and commercial prospects.
- Analysts reacted to the news by slashing Rezolute's rating and price target, with one reportedly moving from outperform to neutral and the price target from $12 to $1.
Dec 30, 2025, 2:30 PM
Rezolute Faces Legal Investigation After Disappointing Clinical Trial Results
RZLT
Legal Proceedings
- Faruqi & Faruqi, LLP is investigating potential claims against Rezolute, Inc. (NASDAQ: RZLT).
- This investigation follows a sharp decline in Rezolute shares on December 11, 2025, due to disappointing topline results from its Phase 3 sunRIZE clinical trial for ersodetug.
- The study, which aimed to treat congenital hyperinsulinism, failed to meet both its primary and key secondary endpoints, with the highest dose showing reductions in hypoglycemia events that were not statistically significant versus placebo.
Dec 24, 2025, 4:50 PM
Rezolute Faces Investigation Following Disappointing Clinical Trial Results
RZLT
Legal Proceedings
Profit Warning
- Faruqi & Faruqi, LLP is investigating potential claims against Rezolute, Inc. (NASDAQ: RZLT).
- The investigation stems from a sharp decline in Rezolute's share price on December 11, 2025, following disappointing topline results from its Phase 3 sunRIZE clinical trial for ersodetug.
- The Phase 3 clinical trial for ersodetug, the company's lead drug candidate for treating congenital hyperinsulinism, failed to meet both its primary and key secondary endpoints.
- Rezolute's shares collapsed from approximately $10.94 to an intraday low near $0.90 on December 11, 2025, representing an 85–90% drop.
Dec 23, 2025, 4:10 PM
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more